ArticleCancer research and treatment2019

Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma.

Changhoon Yoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.